| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 19050 |
| Drug | Larotrectinib |
| Brand | Vitrakvi® |
| Indication | For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. |
| Assessment Process | |
| Rapid review completed | 13/01/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 20/01/2020 |
| Pre-submission consultation with Applicant | 20/04/2020 |
| Full submission received from Applicant | 11/02/2021 |
| Preliminary review sent to Applicant | 16/07/2021 |
| NCPE assessment re-commenced | 30/08/2021 |
| Follow-up to preliminary review sent to Applicant | 10/09/2021 |
| NCPE assessment re-commenced | 15/09/2021 |
| Additional follow-up to Preliminary Review sent to Applicant | 05/10/2021 |
| NCPE assessment re-commenced | 13/10/2021 |
| Factual accuracy sent to Applicant | 22/10/2021 |
| NCPE assessment re-commenced | 03/11/2021 |
| NCPE assessment completed | 23/11/2021 |
| NCPE assessment outcome | The NCPE recommends that larotrectinib (Vitrakvi®) not be recommended for reimbursement, unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
The HSE has approved reimbursement following confidential price negotiations; May 2023
